HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

alniditan

structure given in first source
Also Known As:
N-(3,4-dihydro-2H-1-benzopyran-2-yl methyl)-N'-(1,4,5,6-tetrahydro-2-pyrimidinyl)-1,3-propanediamine dihydrochloride; R 091274; R-091274; R091274
Networked: 10 relevant articles (3 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Study Group: 2 articles (07/2001 - 03/2001)
2. Diener, H C: 2 articles (07/2001 - 03/2001)
3. Tfelt-Hansen, P: 1 article (07/2001)
4. Ferrari, M D: 1 article (07/2001)
5. Dahlöf, C: 1 article (07/2001)
6. de Beukelaar, F: 1 article (07/2001)
7. Olesen, J: 1 article (07/2001)
8. Mathew, N: 1 article (07/2001)
9. De Beukelaar, F: 1 article (03/2001)
10. Schellens, R: 1 article (03/2001)

Related Diseases

1. Migraine Disorders (Migraine)
2. Headache (Headaches)
11/01/1996 - "Time to onset of relief decreased with increasing alniditan dose, and there was a dose-dependent reduction in headache recurrence rate: 25% of patients receiving 1.4 mg had responded by 15 min and headache recurred within 24 h in only 16% of the patients who initially responded to alniditan 1.4 mg, significantly less than for placebo (p = 0.018). "
11/01/1996 - "At 2 h after injection, headache was absent or mild in 83% and 82% of patients receiving alniditan 1.2 and 1.4 mg respectively compared with 39% for placebo (p < or = 0.002). "
03/01/1999 - "To compare the pharmacokinetic profile of intranasal alniditan during and outside migraine attacks, and to investigate the relationship between initial rise of alniditan plasma concentration, and headache improvement. "
11/01/1996 - "Comparison with published findings suggests that alniditan 1.4 mg sc may have advantages over sumatriptan 6 mg sc in providing complete relief from acute migraine headache, and may be associated with fewer headache recurrences within 24 h. "
07/01/2001 - "The number of subjects who were pain free at 2 h (primary endpoint) was: 22 (14.1%) with placebo, 174 (56.3%) with alniditan 1.4 mg, 87 (61.7%) with alnditan 1.8 mg and 209 (65.9%) with sumatriptan 6 mg. Alniditan 1.4 mg was significantly better (P < 0.001) than placebo and sumatriptan was significantly better (P = 0.015) than alniditan 1.4 mg. The number of responders (reduction of headache severity from moderate or severe headache before treatment to mild or absent at 2 h), was 59 (37.8%) on placebo, 250 (80.9%) on alniditan 1.4 mg, 120 (85.1%) on alniditan 1.8 mg, and 276 (87.1%) on sumatriptan. "
3. Glioma (Gliomas)
4. Photophobia (Light Sensitivity)
5. Neurogenic Inflammation

Related Drugs and Biologics

1. Sumatriptan (Imigran)
2. Serotonin (5 Hydroxytryptamine)
3. Dihydroergotamine (Agit)
4. naratriptan
5. indole
6. Serotonin 5-HT1 Receptor Agonists
7. 5-HT1D Serotonin Receptor
8. 5-HT1B Serotonin Receptor
9. Substance P
10. Sodium

Related Therapies and Procedures

1. Subcutaneous Injections
2. Electrodes (Electrode)